• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Inventiva S.A. (Amendment)

    2/13/23 2:07:12 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email
    SC 13G/A 1 tm236518d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2

    (Amendment No. 2) *

     

    Inventiva S.A.

    (Name of Issuer)

     

    Ordinary Shares, nominal value €0.01 per share

    (Title of Class of Securities)

     

    46124U107
    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP NO. 46124U107 Page 2 of 15 Pages
    1

    NAMES OF REPORTING PERSONS

    Sofinnova Crossover I SLP (“SC”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    France

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares), except that Sofinnova Partners SAS, a French corporation (“SP SAS”), the management company of SC, may be deemed to have sole voting power, and Antoine Papiernik (“Papiernik”), Monique Saulnier (“Saulnier”), Cédric Moreau (“Moreau”), Kinam Hong (“Hong”), Thomas Burt (“Burt”), Joseph Anderson (“Anderson”) and Jacques Theurillat (“Theurillat”), the members of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.

     

    7

    SOLE DISPOSITIVE POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares), except that SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, Saulnier, Moreau, Hong, Burt, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to vote these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,381,939 shares

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0% 

    12

    TYPE OF REPORTING PERSON (See Instructions)

    OO

           

     

    CUSIP NO. 46124U107 Page 3 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Sofinnova Partners SAS, a French corporation (“SP SAS”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    France

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, Saulnier, Moreau, Hong, Burt, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.

     

    7

    SOLE DISPOSITIVE POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Saulnier, Moreau, Hong, Burt, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,381,939 shares

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0%

    12

    TYPE OF REPORTING PERSON (See Instructions)

    OO

           

     

    CUSIP NO. 46124U107 Page 4 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Antoine Papiernik (“Papiernik”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    French Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.

     

    7

    SOLE DISPOSITIVE POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,381,939 shares

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0% 

    12

    TYPE OF REPORTING PERSON (See Instructions)

    IN

           

    CUSIP NO. 46124U107 Page 5 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Monique Saulnier (“Saulnier”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    French Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole voting power, and Saulnier, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.

     

    7

    SOLE DISPOSITIVE POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Saulnier, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,381,939 shares

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0% 

    12

    TYPE OF REPORTING PERSON (See Instructions)

    IN

           

     

    CUSIP NO. 46124U107 Page 6 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Cédric Moreau (“Moreau”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    French Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole voting power, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.

     

    7

    SOLE DISPOSITIVE POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,381,939 shares

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0%

    12

    TYPE OF REPORTING PERSON (See Instructions)

    IN

           

    CUSIP NO. 46124U107 Page 7 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Kinam Hong (“Hong”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S.A. Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole voting power, and Hong, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.

     

    7

    SOLE DISPOSITIVE POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Hong, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,381,939 shares

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0% 

    12

    TYPE OF REPORTING PERSON (See Instructions)

    IN

           

    CUSIP NO. 46124U107 Page 8 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Thomas Burt (“Burt”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    British Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole voting power, and Burt, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.

     

    7

    SOLE DISPOSITIVE POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Burt, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,381,939 shares

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0%

    12

    TYPE OF REPORTING PERSON (See Instructions)

    IN

           

    CUSIP NO. 46124U107 Page 9 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Joseph Anderson (“Anderson”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    British Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole voting power, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.

     

    7

    SOLE DISPOSITIVE POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,381,939 shares

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0% 

    12

    TYPE OF REPORTING PERSON (See Instructions)

    IN

           

    CUSIP NO. 46124U107 Page 10 of 15 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Jacques Theurillat (“Theurillat”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Swiss Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole voting power, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.

     

    7

    SOLE DISPOSITIVE POWER

     

    3,381,939 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,381,939 shares

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0%

    12

    TYPE OF REPORTING PERSON (See Instructions)

    IN

           

    CUSIP NO. 46124U107 Page 11 of 15 Pages

     

    Item 1 (a). Name of Issuer: Inventiva S.A.

     

    Item 1 (b).Address of Issuer’s Principal Executive Offices: 50 rue de Dijon, 21121 Daix France.

     

    Item 2 (a).              Name of Person Filing: The persons and entities filing this Amendment No. 2 to Schedule 13G are Sofinnova Crossover I SLP (“SC”), Sofinnova Partners SAS (“SP SAS”), and Antoine Papiernik (“Papiernik”), Monique Saulnier (“Saulnier”), Cédric Moreau (“Moreau), Kinam Hong (“Hong”) , Thomas Burt (“Burt”), Joseph Anderson (“Anderson”) and Jacques Theurillat (“Theurillat”), the members of the investment committee of SC (together with SC and SP SAS, the “Filing Persons”). SP SAS is the management company of SC.

     

    Item 2 (b).              Address of Principal Business Office or, if none, Residence: The address of the principal place of business for each of the Filing Persons is Sofinnova Partners SAS, 7-11 boulevard Hausmann 75009 Paris, France.

     

    Item 2 (c).              Citizenship: SC is a French Partnership. SP SAS is a French Corporation. Papiernik, Saulnier and Moreau are French citizens. Hong is U.S.A. citizen. Burt and Anderson are British citizens. Theurillat is a Swiss citizen.

     

    Item 2 (d).Title of Class of Securities: Ordinary shares, nominal value €0.01 per share.

     

    Item 2 (e).CUSIP Number: 46124U107

     

    Item 3.If this Statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j)¨ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k)¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution.

     

    Not applicable.

     

    CUSIP NO. 46124U107 Page 12 of 15 Pages

     

    Item 4. Ownership

     

    (a)Amount beneficially owned: See Row 9 of the cover page for each of the Filing Persons. Each Filing Person disclaims beneficial ownership with respect to these shares except to the extent of such Filing Person’s pecuniary interest therein.

     

    (b)Percent of class: See Row 10 of the cover page for each of the Filing Persons. Ownership is stated as of December 31, 2022 and the ownership percentages are based on 42,134,169 shares outstanding as of December 31, 2022, as disclosed by Inventiva S.A. in its press release issued on December 31, 2022.

     

    (c)    Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote: See Row 5 of the cover page for each of the Filing Persons.

     

    (ii)Shared power to vote or to direct the vote. See Row 6 of the cover page for each of the Filing Persons.

     

    (iii)Sole power to dispose or to direct the disposition of: See Row 7 of the cover page for each of the Filing Persons.

     

    (iv)Shared power to dispose or to direct the disposition of: See Row 8 of the cover page for each of the Filing Persons.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certifications.

     

    Not Applicable.

     

    CUSIP NO. 46124U107 Page 13 of 15 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of the undersigneds' knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 10, 2023

     

    SOFINNOVA CROSSOVER I SLP   SOFINNOVA PARTNERS SAS
    By: Sofinnova Partners SAS    
             
    By:  /s/ Monique Saulnier   By: /s/ Monique Saulnier
    Name: Monique Saulnier   Name: Monique Saulnier
    Title: Managing Partner   Title: Managing Partner
             
    By: /s/ Antoine Papiernik   By: /s/ Monique Saulnier
    Name: Antoine Papiernik   Name: Monique Saulnier
             
    By: /s/ Cédric Moreau   By: /s/ Kinam Hong
    Name: Cédric Moreau   Name: Kinam Hong
             
    By: /s/ Thomas Burt   By: /s/ Joseph Anderson
    Name: Thomas Burt   Name: Joseph Anderson
             
    By: /s/ Jacques Theurillat      
    Name: Jacques Theurillat      

     

    CUSIP NO. 46124U107 Page 14 of 15 Pages

     

    EXHIBITS

    Exhibit No. Description
       
    99.1 Joint Filing Agreement, dated as of February 10, 2023, by and among Sofinnova Crossover I SLP, Sofinnova Partners SAS, Antoine Papiernik, Monique Saulnier, Cédric Moreau, Kinam Hong, Thomas Burt, Joseph Anderson and Jacques Theurillat.

     

    Get the next $IVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    3/17/2023$27.00Buy
    Stifel
    11/15/2022Buy → Sell
    Societe Generale
    11/22/2021$40.00 → $42.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

      Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the Company's Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will present a corporate overview during a fireside chat at the Jefferies Global Healthcare Conference which will take place in New York on June 4th at 10:30am ET.   The fireside chat will be webcast live and will be access

      5/27/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva reports 2025 First Quarter Financial Information¹

      Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues. Key Financial Results Cash, cash equivalents and deposits As of March 31, 2025, the Company's cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024. The decrease of €28.7 million is  

      5/23/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

      Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the results of the votes of its Combined Shareholders' Meeting.   The Combined Shareholders' Meeting was held on Thursday May 22, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Frédéric Cren, Chief Executive Officer and cofounder of Inventiva. Mr. Frederic Cren proceeded to the usual formalities of the opening of the meetin

      5/23/25 2:00:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

      Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.   Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH.   Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica

      12/16/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

      Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomized in the NATiV3 study evaluating lanifibranor for the treatment of noncirrhotic MASH, with completion of enrollment projected in 1H 2025.Appointment to the Board of Directors of Mark Pruzanski, MD,

      10/14/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the nomination of Andre Turenne as Director

      Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne's appointment will be submitted to the shareholders for ratification at the next general shareholder meeting. Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: "We are extre

      3/28/24 3:00:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Inventiva with a new price target

      TD Cowen initiated coverage of Inventiva with a rating of Buy and set a new price target of $10.00

      2/21/25 8:15:44 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Inventiva with a new price target

      UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00

      11/12/24 7:43:33 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Inventiva with a new price target

      Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00

      10/27/23 7:43:43 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Financials

    Live finance-specific insights

    See more
    • Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

      Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

      5/5/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva reports its 2024 full year results and provides a business update

      Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

      3/26/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

      Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

      3/19/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    SEC Filings

    See more
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/23/25 6:05:05 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/23/25 6:05:06 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/22/25 8:32:34 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 9:00:40 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 8:54:43 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      7/19/24 4:30:23 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care